Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07234942
PHASE1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Sponsor: Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease

Key Details

Gender

All

Age Range

50 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-01-27

Completion Date

2030-03-05

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

RO7812653

Participants will receive RO7812653 as per the schedule in the protocol

DRUG

Placebo

Participants will receive placebo as per the schedule in the protocol

Locations (5)

Brain Research Center Amsterdam

Amsterdam, North Holland, Netherlands

Sahlgrenska Universitetssjukhuset

Mlndal, Sweden

Karolinska Universitetssjukhuset

Solna, Sweden

Southampton General Hospital

Southampton, Hampshire, United Kingdom

National Hospital For Neurology and Neurosurgery

London, United Kingdom